Astrazeneca (AZN) Accumulated Expenses (2015 - 2025)

Astrazeneca (AZN) has reported Accumulated Expenses for 11 consecutive years, with $7.3 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses rose 12.3% year-over-year to $7.3 billion; the TTM figure through Dec 2025 stood at $7.3 billion (up 12.3% YoY), while the FY2025 annual figure was $7.3 billion, up 12.3% from the prior year.
• Accumulated Expenses came in at $7.3 billion for Q4 2025 at Astrazeneca, up from $6.5 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $7.3 billion in Q4 2025, with the low at $911.0 million in Q1 2021.
• Average Accumulated Expenses over 5 years is $5.3 billion, with a median of $5.9 billion recorded in 2021.
• Across the five-year window, Accumulated Expenses soared 44.66% in 2021 and slipped 1.73% in 2022, its largest moves.
• Year by year, Accumulated Expenses stood at $5.6 billion in 2021, then dropped by 1.73% to $5.6 billion in 2022, then rose by 10.11% to $6.1 billion in 2023, then increased by 5.74% to $6.5 billion in 2024, then advanced by 12.3% to $7.3 billion in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $7.3 billion, $6.5 billion, and $6.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.